ArticleVirology journal2025
HBx promotes podocyte-macrophage transdifferentiation by mediating NLRP3 expression in hepatitis B virus-associated glomerulonephritis.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPodocytes are identified as main injury targets in the pathogenesis of hepatitis B virus (HBV)-associated glomerulonephritis (HBV-GN). NLR family pyrin domain containing 3 (NLRP3) has a critical function in inducing podocyte injury across multiple renal pathologies. This study aimed to explore whether NLRP3 expression linked to podocyte injury participated in the pathogenic mechanism of HBV-GN.
methodsThe expression of NLRP3, CD68, intercellular cell adhesion molecule-1 (ICAM-1), and α-smooth muscle actin (α-SMA) was identified in HBV-GN renal biopsies. The correlations between renal NLRP3 expression and clinical parameters, as well as between HBV X (HBx) expression and inflammation and fibrosis markers, were analyzed. HBx-encoding plasmids were transferred into cultured human podocytes. The downstream targets of HBx determined by RNA-sequencing. The expression of NLRP3 and α-SMA was quantified by western blot analysis. The expression of CD68 was detected using immunofluorescence and flow cytometry. Inflammatory factor levels were examined via ELISA.
resultsNLRP3 exhibited a remarkable increase in the podocytes of HBV-GN patients, and its expression showed a significant association with proteinuria levels. Furthermore, co-localization of NLRP3 and CD68 was observed within the podocytes of HBV-GN patients. In vitro, HBx markedly upregulated NLRP3 and induced podocyte-macrophage transdifferentiation (PMT) in human podocytes, thereby contributing to the inflammatory reaction and fibrosis. Further analysis indicated that the NLRP3 inhibitor tranilast (TR) attenuated HBx-induced PMT, inflammation and fibrosis.
conclusionThese findings indicate that HBx triggers NLRP3 upregulation in podocytes and activates PMT. Thereafter, podocytes may function as antigen-presenting cells (APCs), consequently stimulating immune cell activation and resulting in inflammation cascades and renal fibrosis associated with HBV-GN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.